Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

Armata Pharmaceuticals (NYSE American: ARMP), a clinical-stage biotech company developing bacteriophage therapeutics, announced its participation in the upcoming H.C. Wainwright 27th Annual Global Investment Conference. CEO Deborah Birx, M.D. will deliver a corporate presentation on September 10, 2025, from 1:30-2:00 PM ET in New York. The company specializes in developing treatments for antibiotic-resistant and difficult-to-treat bacterial infections.

News Market Reaction

-1.00%

2 alerts

-1.00% News Effect

-11.5% Trough Tracked

-$1M Valuation Impact

$114M Market Cap

1.3x Rel. Volume

On the day this news was published, ARMP declined 1.00%, reflecting a mild negative market reaction. Argus tracked a trough of -11.5% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $114M at that time.

Data tracked by StockTitan Argus on the day of publication.

LOS ANGELES, Sept. 4, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections, today announced that Deborah Birx, M.D., Chief Executive Officer, will participate in a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held in New York from September 8-10, 2025.

Armata's presentation is scheduled for Wednesday, September 10, from 1:30-2:00 PM ET.

To schedule a one-on-one meeting, please contact your H.C. Wainwright representative.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of high-purity pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic including in-house phage-specific current Good Manufacturing Practices manufacturing to support full commercialization.

Media Contacts:

At Armata:
Pierre Kyme
ir@armatapharma.com
310-594-7035

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-27th-annual-global-investment-conference-302540984.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

When is Armata Pharmaceuticals (ARMP) presenting at the H.C. Wainwright Conference 2025?

Armata Pharmaceuticals will present on Wednesday, September 10, 2025, from 1:30-2:00 PM ET at the conference in New York.

Who will be presenting for Armata Pharmaceuticals at the H.C. Wainwright Conference?

Deborah Birx, M.D., Chief Executive Officer of Armata Pharmaceuticals, will deliver the corporate presentation.

What type of therapeutics is Armata Pharmaceuticals (ARMP) developing?

Armata is developing high-purity, pathogen-specific bacteriophage therapeutics for treating antibiotic-resistant and difficult-to-treat bacterial infections.

How can investors arrange meetings with Armata Pharmaceuticals at the conference?

Investors can schedule one-on-one meetings with Armata through their H.C. Wainwright representative.